Recent in-vivo studies conducted in partnership with the University of Toronto confirm Formulation Candidate’s anti-seizure…
Recent in-vivo studies conducted in partnership with the University of Toronto confirm Formulation Candidate’s anti-seizure…
Company also presenting at upcoming investor conferences WATERTOWN, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) —…
Company also presenting at upcoming investor conferences WATERTOWN, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) —…
Reduction of Approximately 20% in Organization Headcount Company Expects to Extend Cash Runway into Q3…
Reduction of Approximately 20% in Organization Headcount Company Expects to Extend Cash Runway into Q3…
CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) — Arbor Biotechnologies, a biotechnology company discovering and…
CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) — Arbor Biotechnologies, a biotechnology company discovering and…
REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage…
REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage…
Roche to receive license for HOOKIPA’s HB-700 program and option to license a second undisclosed…
Roche to receive license for HOOKIPA’s HB-700 program and option to license a second undisclosed…
SCYNEXIS is announcing a new strategic direction to refocus its resources on the clinical development…
SCYNEXIS is announcing a new strategic direction to refocus its resources on the clinical development…
BOSTON and LOUISVILLE, Ky., Oct. 20, 2022 (GLOBE NEWSWIRE) — Talaris Therapeutics, Inc. (Nasdaq: TALS),…
BOSTON and LOUISVILLE, Ky., Oct. 20, 2022 (GLOBE NEWSWIRE) — Talaris Therapeutics, Inc. (Nasdaq: TALS),…
CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader…
CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader…
Agreements Showcase Company’s Ability to Support Novel Therapeutic Programs Regardless of Development Stage; Services Focused…
Agreements Showcase Company’s Ability to Support Novel Therapeutic Programs Regardless of Development Stage; Services Focused…